Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat? | Zendy

Ben A. van Hout | Zendy; M. L. Simoons | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat?

Author(s) -

Ben A. van Hout,

M. L. Simoons

Publication year - 2001

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1053/euhj.2000.2308

Subject(s) - medicine , hmg coa reductase , reductase , hydroxymethylglutaryl coa reductase , pharmacology , coenzyme a , hydroxymethylglutaryl coa reductase inhibitors , biochemistry , enzyme , statin , chemistry

Treatment guidelines have been developed for both "primary" and "secondary" prevention of coronary heart disease. These should consider both the efficacy as well as the costs of such treatment, particularly the costs of treatment with HMG co-enzyme A reductase inhibitors (statins). In the context of guideline development in The Netherlands, the cost effectiveness of treatment with statins was analysed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research